The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Doxorubicin and Paclitaxel Versus Fluorouracil, Doxorubicin, and Cyclophosphamide as First-Line Therapy for Women With Metastatic Breast Cancer: Final Results of a Randomized Phase III Multicenter Trial
Abstract
PURPOSE: This phase III trial compared the efficacy and safety of doxorubicin and paclitaxel (AT) to 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) as first-line therapy for women with metastatic breast cancer. PATIENTS AND METHODS: A total of 267 women with metastatic breast cancer were randomized to receive either AT (doxorubicin 50 mg/m 2 followed 24 hours later by paclitaxel 220 mg/m 2) or FAC (5-fluorouracil 500 mg/m 2, doxorubicin 50 mg/m 2, cyclophosphamide 500 mg/m 2), each administered every 3 weeks for up to eight cycles. Patients had to have measurable disease and an Eastern Cooperative Oncology Group performance status of 0 to 2. Only one prior non–anthracycline, nontaxane-containing adjuvant chemotherapy regimen was allowed. RESULTS: Overall response rates for patients randomized to AT and FAC were 68% and 55%, respectively (P = .032). Median time to progression and overall survival were significantly longer for AT compared with FAC (time to progression 8.3 months v 6.2 months [P = .034]; overall survival 23.3 months v 18.3 months [P = .013]). Therapy was generally well-tolerated (median of eight cycles delivered in each arm). Grade 3 or 4 neutropenia was more common with AT than with FAC (89% v 65%; P < .001); however, the incidence of fever and infection was low. Grade 3 or 4 arthralgia and myalgia, peripheral neuropathy, and diarrhea were more common with AT, whereas nausea and vomiting were more common with FAC. The incidence of cardiotoxicity was low in both arms. CONCLUSION: AT conferred a significant advantage in response rate, time to progression, and overall survival compared with FAC. Treatment was well-tolerated with no unexpected toxicities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
A Confidence Interval for the Median Survival Time
Brookmeyer, R., & Crowley, J. (1982) · Biometrics · doi:10.2307/2530286 · Cited by 914
THE IMPACT OF NATIONAL CANCER ACT
(1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.24.1797 · Cited by 796
Hortobagyi, G. N. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810013391407 · Cited by 781
Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast Cancer
Holmes, F. A., Walters, R. S., Theriault, R. L., Buzdar, A. U., Frye, D. K., Hortobagyi, G. N., Forman, A. D., Newton, L. K., & Raber, M. N. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.24.1797-a · Cited by 746
Greenberg, P. A., Hortobagyi, G. N., Smith, T. L., Ziegler, L. D., Frye, D. K., & Buzdar, A. U. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.8.2197 · Cited by 738
Chan, S., Friedrichs, K., Noel, D., Pintér, T., Van Belle, S., Vorobiof, D., Duarte, R., Gil Gil, M., Bodrogi, I., Murray, E., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2341 · Cited by 641
Gianni, L., Munzone, E., Capri, G., Fulfaro, F., Tarenzi, E., Villani, F., Spreafico, C., Laffranchi, A., Caraceni, A., & Martini, C. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.11.2688 · Cited by 553
Fossati, R., Confalonieri, C., Torri, V, Ghislandi, E., Penna, A., Pistotti, V, Tinazzi, A., & Liberati, A. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.10.3439 · Cited by 546
Nabholtz, J.-M., Senn, H. J., Bezwoda, W. R., Melnychuk, D., Deschênes, L., Douma, J., Vandenberg, T. A., Rapoport, B., Rosso, R., Trillet-Lenoir, V., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.5.1413 · Cited by 508
Self-citationNabholtz, J. M., Gelmon, K., Bontenbal, M., Spielmann, M., Catimel, G., Conte, P., Klaassen, U., Namer, M., Bonneterre, J., Fumoleau, P., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.6.1858 · Cited by 380
Gianni, L., Viganò, L., Locatelli, A., Capri, G., Giani, A., Tarenzi, E., & Bonadonna, G. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.5.1906 · Cited by 278
Combined doxorubicin and paclitaxel in advanced breast cancer: Effective and cardiotoxic
Gehl, J., Boesgaard, M., Paaske, T., Vittrup Jensen, B., & Dombernowsky, P. (1996) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a010717 · Cited by 247
Reichman, B. S., Seidman, A. D., Crown, J. P., Heelan, R., Hakes, T. B., Lebwohl, D. E., Gilewski, T. A., Surbone, A., Currie, V, & Hudis, C. A. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.10.1943 · Cited by 237
Bishop, J. F., Dewar, J., Toner, G. C., Smith, J., Tattersall, M. H. N., Olver, I. N., Ackland, S., Kennedy, I., Goldstein, D., Gurney, H., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2355 · Cited by 209
Seidman, A. D., Tiersten, A., Hudis, C., Gollub, M., Barrett, S., Yao, T. J., Lepore, J., Gilewski, T., Currie, V, & Crown, J. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.10.2575 · Cited by 203
A'Hern, R., Smith, I., & Ebbs, Sr. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.146 · Cited by 199
Combining Dependent Tests with Incomplete Repeated Measurements
Wei, L. J., & Johnson, W. E. (1985) · Biometrika · doi:10.2307/2336088 · Cited by 188
(1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.4.679 · Cited by 180
Combining dependent tests with incomplete repeated measurements
WEI, L. J., & JOHNSON, W. E. (1985) · Biometrika · doi:10.1093/biomet/72.2.359 · Cited by 177
(1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.6.976 · Cited by 167
Gianni, L., Munzone, E., Capri, G., Villani, F., Spreafico, C., Tarenzi, E., Fulfaro, F., Caraceni, A. T., Martini, C., Laffranchi, A., et al. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.15.1169 · Cited by 144
Bennett, J. M., Muss, H. B., Doroshow, J. H., Wolff, S., Krementz, E. T., Cartwright, K. J., Dukart, G., Reisman, A., & Schoch, I. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.10.1611 · Cited by 109
Fumoleau, P., Chevallier, B., Kerbrat, P., Krakowski, Y., Misset, J. L., Maugard, C. M., Dieras, V. C., Azli, N., Bougon, N., Riva, A., et al. (1996) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a010544 · Cited by 100
Dieras, V. C., Chevallier, B., Kerbrat, P., Krakowski, I., Roche, H. H., Misset, J. L., Lentz, M.-A., Azli, N., Murawsky, M., Riva, A., et al. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.416 · Cited by 84
Sparano, J. A., O’Neill, A., Schaefer, P., Falkson, C. I., & Wood, W. C. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.12.2369 · Cited by 69
Alonso, M. C., Tabernero, J. M., Ojeda, B., Llanos, M., Sol�, C., Climent, M. A., Seguí, M. Á., & L�pez, J. (1995) · Breast Cancer Research and Treatment · doi:10.1007/bf00666487 · Cited by 27
Cited by
Aapro, M. S., Bohlius, J., Cameron, D. A., Lago, L. D., Donnelly, J. P., Kearney, N., Lyman, G. H., Pettengell, R., Tjan-Heijnen, V. C., Walewski, J., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2010.10.013 · Cited by 1,090
Extending Survival with Chemotherapy in Metastatic Breast Cancer
O'Shaughnessy, J. (2005) · The Oncologist · doi:10.1634/theoncologist.10-90003-20 · Cited by 668
Roché, H., Fumoleau, P., Spielmann, M., Canon, J.-L., Delozier, T., Serin, D., Symann, M., Kerbrat, P., Soulié, P., Eichler, F., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.3916 · Cited by 577
Randomized Phase III Study of Docetaxel Compared With Paclitaxel in Metastatic Breast Cancer
Jones, S. E., Erban, J., Overmoyer, B., Budd, G. T., Hutchins, L., Lower, E., Laufman, L., Sundaram, S., Urba, W. J., Pritchard, K. I., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.027 · Cited by 547
Aapro, M. S., Cameron, D. A., Pettengell, R., Bohlius, J., Crawford, J., Ellis, M., Kearney, N., Lyman, G. H., Tjan-Heijnen, V. C., Walewski, J., et al. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.05.002 · Cited by 539
Metadata
- Authors
- Jassem, J., Pieńkowski, T., Płuzańska, A., Jelic, S., Gorbunova, V., Mrsic-Krmpotic, Z., Berzins, J., Nagykalnai, T., Wigler, N., Renard, J., Munier, S., & Weil, C.
- Venue
- Journal of Clinical Oncology
- Published
- 2001-03-15
- Volume
- 19
- Issue
- 6
- Pages
- 1707-1715
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1923449517
- Cited by
- 308
- References
- 28
- FWCI
- 11.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.